The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Leg Ulcer

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Leg Ulcer


High impact information on Leg Ulcer

  • In addition, the leg ulcer healed; his WBC count, hemoglobin level, temperature, ESR, and weight returned to normal; the rheumatoid factor titer dropped substantially; and the antinuclear antibodies disappeared [6].
  • Pentoxifylline for treatment of venous leg ulcers: a systematic review [7].
  • Five consecutive patients with cryofibrinogenaemia in association with painful leg ulcers and intravascular dermal thrombi were treated with stanozolol, an androgenic steroid with fibrinolytic properties [8].
  • Topical prostaglandin E2 for chronic leg ulcers [9].
  • Wound healing produced by isotonic saline irrigation via a special dressing was compared with that produced by conventional saline dressings in 12 inpatients with 18 leg ulcers [10].

Chemical compound and disease context of Leg Ulcer


Biological context of Leg Ulcer


Anatomical context of Leg Ulcer


Gene context of Leg Ulcer


Analytical, diagnostic and therapeutic context of Leg Ulcer


  1. NGF, a useful tool in the treatment of chronic vasculitic ulcers in rheumatoid arthritis. Tuveri, M., Generini, S., Matucci-Cerinic, M., Aloe, L. Lancet (2000) [Pubmed]
  2. Pseudomonas aeruginosa exotoxin A antibodies in rapidly deteriorating chronic leg ulcers. Danielsen, L., Westh, H., Balselv, E., Rosdahl, V.T., Döring, G. Lancet (1996) [Pubmed]
  3. Vasculitic leg ulcers in chronic myelogenous leukemia. Stahl, R.L., Silber, R. Am. J. Med. (1985) [Pubmed]
  4. Physiologic and therapeutic aspects in congenital vein valve aplasia of the lower limb. Plate, G., Brudin, L., Eklöf, B., Jensen, R., Ohlin, P. Ann. Surg. (1983) [Pubmed]
  5. The effects of serum iminodipeptides and prednisolone on superoxide generation and tyrosyl phosphorylation of proteins in neutrophils from a patient with prolidase deficiency. Zhang, J., Sugahara, K., Yasuda, K., Kodama, H., Sagara, Y., Kodama, H. Free Radic. Biol. Med. (1998) [Pubmed]
  6. Improvement of rheumatoid arthritis following splenectomy for Felty syndrome. Khan, M.A., Kushner, I. JAMA (1977) [Pubmed]
  7. Pentoxifylline for treatment of venous leg ulcers: a systematic review. Jull, A., Waters, J., Arroll, B. Lancet (2002) [Pubmed]
  8. Stanozolol in treatment of leg ulcers due to cryofibrinogenaemia. Falanga, V., Kirsner, R.S., Eaglstein, W.H., Katz, M.H., Kerdel, F.A. Lancet (1991) [Pubmed]
  9. Topical prostaglandin E2 for chronic leg ulcers. Eriksson, G., Johansson, C., Aly, A. Lancet (1986) [Pubmed]
  10. Irrigation treatment of leg ulcers. Svedman, P. Lancet (1983) [Pubmed]
  11. Letter: Zinc-65 retention in patients with stasis leg ulcers. Hawkins, T., Marks, J. Lancet (1976) [Pubmed]
  12. Hydroxyurea-induced leg ulcers treated with Apligraf. Flores, F., Eaglstein, W.A., Kirsner, R.S. Ann. Intern. Med. (2000) [Pubmed]
  13. L-carnitine for leg ulcers. Harrell, H.L. Ann. Intern. Med. (1990) [Pubmed]
  14. Accelerated healing of chronic sickle-cell leg ulcers treated with RGD peptide matrix. RGD Study Group. Wethers, D.L., Ramirez, G.M., Koshy, M., Steinberg, M.H., Phillips, G., Siegel, R.S., Eckman, J.R., Prchal, J.T. Blood (1994) [Pubmed]
  15. Pyruvate kinase deficiency and leg ulcers. Müller-Soyano, A., Tovar de Roura, E., Duke, P.R., De Acquatella, G.C., Arends, T., Guinto, E., Beutler, n.u.l.l. Blood (1976) [Pubmed]
  16. Expression of cyclooxygenase isoforms in normal human skin and chronic venous ulcers. Abd-El-Aleem, S.A., Ferguson, M.W., Appleton, I., Bhowmick, A., McCollum, C.N., Ireland, G.W. J. Pathol. (2001) [Pubmed]
  17. Venous leg ulcers and apoptosis: a TIMP-3-mediated pathway? Herouy, Y., Kahle, B., Idzko, M., Hildenbrand, T., Ali, M.Y., Clement, J., Ferrari, D., Di Virgilio, F., Bruckner-Tuderman, L., Norgauer, J. J. Invest. Dermatol. (2004) [Pubmed]
  18. Differential effects of acute and chronic wound fluids on urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and tissue-type plasminogen activator in cultured human keratinocytes and fibroblasts. Weckroth, M., Vaheri, A., Myöhänen, H., Tukiainen, E., Sirén, V. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society. (2001) [Pubmed]
  19. A new clinical trial of the effect of larval therapy. Raynor, P., Dumville, J., Cullum, N. Journal of tissue viability. (2004) [Pubmed]
  20. Local treatment of venous ulcers with tissue type plasminogen activator containing ointment. Zeegelaar, J.E., Verheijen, J.H., Kerckhaert, J.A., Jankowski, I., Faber, W.R. VASA (1997) [Pubmed]
  21. Matrix metalloproteinases, gelatinase and collagenase, in chronic leg ulcers. Weckroth, M., Vaheri, A., Lauharanta, J., Sorsa, T., Konttinen, Y.T. J. Invest. Dermatol. (1996) [Pubmed]
  22. Wound fluid from venous leg ulcers degrades plasminogen and reduces plasmin generation by keratinocytes. Hoffman, R., Starkey, S., Coad, J. J. Invest. Dermatol. (1998) [Pubmed]
  23. Atypical osteosarcomas in Werner Syndrome (adult progeria). Ishikawa, Y., Miller, R.W., Machinami, R., Sugano, H., Goto, M. Jpn. J. Cancer Res. (2000) [Pubmed]
  24. Autologous platelet-derived wound healing factor promotes angiogenesis via alphavbeta3-integrin expression in chronic wounds. Herouy, Y., Mellios, P., Bandemir, E., Stetter, C., Dichmann, S., Idzko, M., Hofmann, C., Vanscheidt, W., Schopf, E., Norgauer, J. Int. J. Mol. Med. (2000) [Pubmed]
  25. Level of fibronectin mRNA is markedly increased in human chronic wounds. Ongenae, K.C., Phillips, T.J., Park, H.Y. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. (2000) [Pubmed]
  26. Levels of tumor necrosis factor-alpha (TNF-alpha) and soluble TNF receptors in chronic venous leg ulcers--correlations to healing status. Wallace, H.J., Stacey, M.C. J. Invest. Dermatol. (1998) [Pubmed]
  27. Plasminogen activation in venous leg ulcers. Herouy, Y., Trefzer, D., Hellstern, M.O., Stark, G.B., Vanscheidt, W., Schöpf, E., Norgauer, J. Br. J. Dermatol. (2000) [Pubmed]
  28. Elevated expression of extracellular matrix metalloproteinase inducer (CD147) and membrane-type matrix metalloproteinases in venous leg ulcers. Norgauer, J., Hildenbrand, T., Idzko, M., Panther, E., Bandemir, E., Hartmann, M., Vanscheidt, W., Herouy, Y. Br. J. Dermatol. (2002) [Pubmed]
  29. The impact of differential expression of extracellular matrix metalloproteinase inducer, matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2 and PDGF-AA on the chronicity of venous leg ulcers. Mwaura, B., Mahendran, B., Hynes, N., Defreitas, D., Avalos, G., Adegbola, T., Adham, M., Connolly, C.E., Sultan, S. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery. (2006) [Pubmed]
  30. The terminal complement complex is generated in chronic leg ulcers in the absence of protectin (CD59). Balslev, E., Thomsen, H.K., Danielsen, L., Sheller, J., Garred, P. APMIS (1999) [Pubmed]
  31. Iron and 8-isoprostane levels in acute and chronic wounds. Yeoh-Ellerton, S., Stacey, M.C. J. Invest. Dermatol. (2003) [Pubmed]
  32. Efficacy of the treatment with prostaglandin E-1 in venous ulcers of the lower limbs. Milio, G., Minà, C., Cospite, V., Almasio, P.L., Novo, S. J. Vasc. Surg. (2005) [Pubmed]
  33. Adverse effects associated with EMLA cream used as topical anesthetic for the mechanical debridement of leg ulcers. Boulinguez, S., Sparsa, A., Bouyssou-Gauthier, M.L., Bedane, C., Bonnetblanc, J.M. J. Am. Acad. Dermatol. (2000) [Pubmed]
  34. Proteolytic inactivation of transforming growth factor beta3 by elastase in venous leg ulcers: implications for clinical trials using topically-applied peptide growth factors. Schmid, P., Itin, P., Cox, D. Br. J. Dermatol. (1999) [Pubmed]
  35. Granulocyte/macrophage colony-stimulating factor treatment of human chronic ulcers promotes angiogenesis associated with de novo vascular endothelial growth factor transcription in the ulcer bed. Cianfarani, F., Tommasi, R., Failla, C.M., Viviano, M.T., Annessi, G., Papi, M., Zambruno, G., Odorisio, T. Br. J. Dermatol. (2006) [Pubmed]
WikiGenes - Universities